This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zanotti, K. M. Articles by Markman, M. Search for Related Content PubMed PubMed Citation Articles by Zanotti, K. M. Articles by Markman, M. Social Bookmarking                            What's this?

Carboplatin Skin Testing: A Skin-Testing Protocol for Predicting Hypersensitivity to Carboplatin Chemotherapy

From The Cleveland Clinic Foundation, Cleveland, OH.

Address reprint requests to Kristine Zanotti, MD, The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk A81, Cleveland, OH 44012; email: zanottk{at}.ccf.org

PURPOSE: A high incidence of moderate to severe hypersensitivity reactions (HRs) is noted in patients who have been treated with multiple courses of carboplatin. Presently, there is no reliable way to predict which patients may be at risk for this potentially severe adverse reaction. We developed a skin-test protocol to identify patients at high risk for HR to carboplatin chemotherapy.

PATIENTS AND METHODS: Patients undergoing more than seven courses of carboplatin received a 0.02-mL intradermal injection of an undiluted aliquot of their planned carboplatin infusion 1 hour before each course of the agent. A positive skin test was prospectively defined as that resulting in a wheel of at least 5 mm with a surrounding flare. We recently reported a 27% incidence of HRs in patients receiving more than seven courses of carboplatin. These patients served as historical controls for the current study.

RESULTS: Forty-seven patients with recurrent ovarian or primary peritoneal carcinoma receiving carboplatin were skin tested. Thirteen of 47 patients (28%) manifested a positive skin test at a median of nine total courses of carboplatin (range, eight to 17 courses). This rate of skin-test positivity was not significantly different from the incidence of documented HR reported in a historical control group (P = .89), suggesting comparable populations. A negative skin test accurately predicted the absence of HR in 166 of 168 courses of chemotherapy. Only two of 47 patients (4%) experienced a HR after a negative skin test. Thus, administering carboplatin only to patients with a negative skin test may result in a significant reduction in HRs relative to historical controls (P = .002).

CONCLUSION: An easily performed skin test appears to predict patients in whom carboplatin may be safely administered. Treatment modifications based on the results of skin testing may reduce the incidence of HRs in patients receiving repeated courses of carboplatin.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Markman, J. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design J. Clin. Oncol., August 1, 2004; 22(15): 3120 - 3125. [Abstract] [Full Text] [PDF]

				M. Markman, K. Zanotti, G. Peterson, B. Kulp, K. Webster, and J. Belinson Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity J. Clin. Oncol., December 15, 2003; 21(24): 4611 - 4614. [Abstract] [Full Text] [PDF]

				C. Garufi, A. Cristaudo, B. Vanni, E. Bria, A. M. Aschelter, B. Santucci, and E. Terzoli Skin testing and hypersensitivity reactions to oxaliplatin Ann. Onc., March 1, 2003; 14(3): 497 - 498. [Full Text] [PDF]

				M. Gutierrez, P. Pautier, and C. Lhomme Replacement of Carboplatin by Oxaliplatin May be One Solution for Patients Treated for Ovarian Carcinoma Who Are Hypersensitive to Carboplatin J. Clin. Oncol., January 1, 2002; 20(1): 353 - 353. [Full Text] [PDF]